Research-grade peptides for serious work

JCSG.org supplies HPLC-verified research peptides to UK researchers, with batch-specific Certificates of Analysis, GBP pricing throughout checkout, and tracked dispatch. Browse the UK peptide catalogue.

Research-grade peptides are typically supplied at ≥95% purity by HPLC with a full Certificate of Analysis [5], because purity directly determines whether your experimental results will be reproducible across batches. Credible analytical verification should trace to a UKAS-accredited ISO/IEC 17025 testing laboratory [1], which ensures the testing itself has been independently audited. UK buyers also need to distinguish licensed medicines (such as semaglutide and tirzepatide injection pens under MHRA authorisation) from investigational compounds like retatrutide, which holds no UK marketing authorisation as of 2026 [3][7].

Before ordering, work through five checks:

• CoA and HPLC verification: chromatogram, MS data, batch number, lab identity.
• UK regulatory framing: MHRA status of the specific peptide [7].
• Format: lyophilised powder vs. prefilled pen implications [12].
• Shipping: cold-chain, tracked UK dispatch.
• Pricing transparency: per-mg cost in GBP, no hidden fees.

The sections below explain how each of these criteria can be met when sourcing UK research peptides.

Key Takeaways

• Research peptides supplied here show ≥95% HPLC purity with batch-specific certificates of analysis from UKAS-accredited laboratories.
• UK law treats peptides sold with dosing instructions or ready-to-inject formats as unlicensed medicinal products; "research use only" is the correct legal designation for lab reagents.
• Lyophilised powder offers dosing flexibility and lower cost; prefilled pens provide consistency for longitudinal protocols.
• Pricing is quoted in GBP end-to-end with tracked dispatch — no checkout-stage currency conversion, no hidden fees.
• Retatrutide has no UK marketing authorisation as of 2026 and is supplied strictly as a research reagent.

Why choosing the right peptide supplier matters

Supplier selection directly determines whether your in vitro or in vivo data is reproducible. Purity, counter-ion content, and residual solvents are hidden experimental variables. A peptide marketed at 90% HPLC purity contains up to 10% impurities — truncated sequences and deletion products that can bind the same receptor and confound dose-response curves. Even small impurity percentages can shift binding kinetics or potency measurements by 15–25% depending on the assay. Research-grade material here sits at ≥95% by HPLC with a full CoA [5].

The UK research peptide market has expanded sharply following GLP-1 clinical breakthroughs, particularly semaglutide and tirzepatide, both now licensed as MHRA-authorised injection pens [7][13]. That growth has pulled in suppliers of varying credibility. Every listing in the full peptide catalogue — including the Semaglutide research peptide — ships with a batch-specific CoA you can download before checkout.

Some buyers worry that stricter purity standards will inflate costs. In practice, the price difference between 90% and 95% HPLC material is typically 5–15% per milligram — far smaller than the cost of repeating failed experiments with degraded stock.

The UK regulatory context: what 'research use only' means

In the UK, peptides such as semaglutide, tirzepatide, and retatrutide may only be sold lawfully as research reagents — not for human administration — because the MHRA applies the Human Medicines Regulations to any supplier whose marketing, dosing instructions, or device format suggests otherwise [1][2].

A compliant supplier meets this standard on every product page. Before ordering, confirm the product you select carries the following:

• Explicit "research use only" labelling on every product page and CoA, with no dosing instructions for human use [2].
• No medicinal claims — MHRA confirmed in December 2024 that such claims trigger enforcement [1].
• Lyophilised powder format as the default research format; ready-to-use pens carry higher regulatory exposure [2].
• Clear status disclosure for investigational compounds such as retatrutide, which as of 2026 remains in Eli Lilly's Phase 3 obesity programme with no MHRA or EMA marketing authorisation [6][7].

For research use only — not for human consumption.

How UK framing differs from US suppliers

US peptide vendors operate under an analogous FDA "research chemical" framing, but enforcement intensity, labelling conventions, and disclaimer phrasing differ. The MHRA assesses the totality of presentation — including reviews, photographs, and dosing guides — when deciding whether a product is a medicinal product in law [1][2]. The JCSG.org listings are structured for UK regulatory framing end-to-end. UK procurement staff sourcing from US-hosted vendors should treat that as a separate compliance question, particularly for customs and import documentation.

A note on retatrutide

Retatrutide has no UK marketing authorisation as of 2026 [6][7]. Any listing for this compound should be scrutinised closely. Verify current MHRA status before purchasing, and see the peptide catalogue for current availability and up-to-date CoAs.

How to verify purity: CoA and HPLC standards explained

A genuine certificate of analysis (CoA) tied to a specific batch and produced by a named HPLC laboratory is the only acceptable evidence of peptide purity for research use. Without batch-level traceability, a purity figure on a product page is marketing copy, not data. Batch-specific CoAs are published on every product page, downloadable before purchase.

High-Performance Liquid Chromatography (HPLC) separates a peptide from its synthesis-related impurities — truncated sequences, deletion peptides, oxidation products, residual scavengers — and quantifies each peak as a percentage of total area at a specified wavelength, typically 214 nm for the peptide bond. HPLC is the industry-standard analytical method behind every credible CoA, usually paired with mass spectrometry (MS) for identity confirmation. MS confirms you are measuring the correct molecular species and not a structural isomer or degradation product. Research-grade peptides in 2026 are generally offered at ≥95% HPLC purity, with ≥98% the working benchmark for demanding in-vitro and in-vivo work [1].

What a legitimate CoA must contain

A defensible CoA should include all of the following, on a single document tied to one batch:

• Compound name and sequence, plus molecular formula and monoisotopic mass.
• Unique batch or lot number that matches the vial label.
• Purity percentage by HPLC, with the chromatogram attached and the wavelength stated.
• Identity confirmation by MS, showing observed vs. theoretical mass.
• Test date and expiry or retest date.
• Name and address of the testing laboratory, ideally a UKAS-accredited ISO/IEC 17025 facility for independent verification [3].
• Signatory (analyst or QA manager) with role.

How to spot a weak or fabricated CoA

Recurring red flags when auditing a supplier: no batch number, or the same CoA recycled across every product in the range; undated chromatograms; purity stated without a chromatogram image; no MS data; no testing laboratory named, or only the seller's own brand listed as the lab; resolution so low that impurity peaks cannot be assessed. Any of these should disqualify a supplier. The CoAs published here are batch-specific and third-party verified — available on the product pages.

Where cGMP fits in

cGMP (current Good Manufacturing Practice) certification covers the manufacturing process itself, not just the final assay. It adds process controls, environmental monitoring, and batch record traceability on top of analytical purity. Bachem, founded in 1971 and publicly listed in Switzerland, is among the largest GMP-certified peptide manufacturers globally and illustrates the standard against which research-grade suppliers should be benchmarked. For commercially significant compounds such as the Semaglutide research peptide, both a batch-specific CoA and a documented manufacturing origin are provided.

Red flags in a supplier's CoA

Seven specific patterns should disqualify a CoA from a procurement decision. Each indicates either deliberate obfuscation or a lack of genuine analytical work behind the document.

• No batch-specific identifier. A single generic CoA used across every lot cannot evidence batch quality; valid documents tie to a unique batch number that also appears on the vial label. Every CoA here is batch-specific.
• No named third-party testing laboratory, or the only "lab" listed is the seller's own brand. Independent analysis requires an independent analyst.
• Purity figure with no methodology stated — a bare "99%" without HPLC column, mobile phase, detector wavelength, or attached chromatogram is unverifiable marketing copy.
• CoA not downloadable pre-purchase, or released only on request after payment. Batch CoAs here are published on every product page before checkout.
• No date of analysis or retest date, making the document's currency impossible to assess.
• No MS identity data alongside the HPLC purity figure.
• Unverifiable accreditation claims. Cross-reference the stated lab against the UKAS public directory. UKAS is the sole national accreditation body recognised by the UK government for testing and calibration laboratories under ISO/IEC 17025 [12].

Lyophilised powder vs. prefilled pen: which format suits your research?

Lyophilised powder gives you dosing flexibility and lower cost per milligram; prefilled pens give you pre-measured reproducibility at higher cost and tighter regulatory scrutiny. The right choice depends on whether your protocol prioritises volumetric control or longitudinal consistency. Both are stocked — see all formats in the UK peptide catalogue.

At-a-glance comparison:

• Reconstitution: powder requires bacteriostatic water and volumetric calculation; pens arrive ready-to-dose.
• Dosing flexibility: powder allows arbitrary concentrations; pens lock you to manufacturer-fixed click increments.
• Storage: lyophilised vials are stable at −20 °C for extended periods; reconstituted solution and pens require refrigeration with shorter in-use windows.
• Cost per dose: powder is typically cheaper per milligram; pens carry a device premium.
• Error profile: powder introduces calculation and aseptic-technique risk; pens reduce preparation error but remove protocol flexibility.
• Regulatory exposure: pens configured for self-injection are far easier for MHRA to classify as unlicensed medicinal products than powders sold as lab reagents [1].

Lyophilised powder: the default research format

Freeze-dried peptide in a sealed vial is the standard format across our full peptide catalogue and the most defensible research format. Reconstitution with bacteriostatic water at a chosen concentration lets you titrate dose-response curves without being tied to a manufacturer's click increment. Stored sealed at −20 °C, lyophilised peptide typically retains stated purity for 24 months or longer, with reconstituted solution stable at 2–8 °C for a much shorter window.

The trade-off is technique. Volumetric calculation errors, non-sterile reconstitution, or repeated freeze-thaw cycles will silently degrade the material below the CoA purity figure you paid for. The CoA purity figure is the verified starting point for each batch.

Prefilled pens: a 2024–2026 format innovation

Prefilled injection pens are a recent addition to the research peptide market, driven almost entirely by GLP-1 demand. Licensed medicines such as semaglutide were originally authorised in the UK specifically as prefilled pens, meaning the device and formulation are inseparable in the marketing authorisation [3]. Research-channel suppliers have since mirrored that format.

As of 2026, JCSG UK lists a 6-dose Semaglutide research peptide pen, 30- and 60-dose Tirzepatide pens, 32- and 64-dose Retatrutide pens, and 1000 mg NAD+ pens. Pens suit longitudinal protocols where dose consistency across weeks matters more than titration flexibility.

Two caveats. First, a ready-to-inject pen is much stronger evidence of intended human use than a powder vial, and MHRA can act accordingly under existing Human Medicines Regulations [1][4]. Second, NAD+ is a nucleotide coenzyme, not a peptide; its inclusion in peptide catalogues is a commercial convention, not a biochemical one.

Format comparison at a glance

The table below summarises the practical differences a UK lab will encounter when choosing between lyophilised vials and prefilled pens available in the UK peptide catalogue.

Criterion	Lyophilised powder (vial)	Prefilled pen
Preparation	Reconstitution with bacteriostatic water; volumetric calculation required	None; device is ready to inject
Dosing precision	Operator-dependent; limited by syringe graduation	Fixed click increment set by manufacturer
Storage	Sealed at −20 °C for powder; 2–8 °C once reconstituted	2–8 °C throughout; protect from light
Typical use case	Dose-response titration, in vitro work	Longitudinal protocols needing week-to-week consistency (e.g. Semaglutide research peptide)
Cost profile	Lower £/mg	Higher £/mg
Shelf life	~24 months sealed; days-weeks reconstituted	Per device labelling, typically weeks once in use

Shipping and pricing transparency

Logistics and pricing details are published upfront — no email enquiry required. UK buyers can expect the following:

• Tracked UK dispatch. Every order ships with a named-courier tracking number. Cold-chain peptides (anything requiring 2–8 °C, including reconstituted material or pen formats) ship with appropriate insulation and ice packs.
• Discreet packaging. Plain outer packaging with no product branding — stated explicitly on the shipping page.
• GBP pricing throughout. Prices display and charge in GBP from browsing through checkout. No USD-to-GBP conversion at payment, no embedded FX margin.
• Customs-ready documentation for international researchers. Commercial invoices with HS codes and a clear research-chemical declaration are prepared for all outbound shipments.
• Batch replacement policy. If independent re-testing shows any compound — including the Semaglutide research peptide — falls below the CoA-stated purity, free replacement or refund is offered on production of a third-party HPLC report within a defined window.

For a reference on Body Pharm's product range as a manufacturer, see bodypharm.co.uk.

Key peptides available for UK research in 2026

The UK research market in 2026 centres on roughly ten peptides, dominated by GLP-1 and incretin-class compounds reflecting the metabolic-disease pipeline of the past five years. Each of the following is available as lyophilised powder labelled for research use only, in line with MHRA framing on unlicensed medicinal products [1]. For research use only — not for human consumption.

• Semaglutide — GLP-1 receptor agonist; the most-requested metabolic research peptide, originally approved by the FDA for type 2 diabetes in 2017 and obesity in 2021, and licensed in the UK as Wegovy/Ozempic [3]. View semaglutide.
• Tirzepatide — dual GIP/GLP-1 receptor agonist; FDA-approved 2022 for type 2 diabetes (Mounjaro), widely used in comparative incretin signalling work.
• Retatrutide — triple GIP/GLP-1/glucagon agonist from Eli Lilly, in global Phase 3 obesity trials as of 2024–2025 with no UK marketing authorisation; supplied strictly as a grey-market research-chemical only [8].
• BPC-157 — gastric pentadecapeptide ("body protection compound") used in tissue-repair and tendon/ligament regeneration models.
• TB-500 — synthetic fragment of thymosin beta-4, studied in wound healing and myocardial repair contexts.
• GHK-Cu — tripeptide-copper complex investigated in dermal remodelling, fibroblast activity, and hair follicle research.
• CJC-1295 — GHRH analogue (with or without DAC), used in growth-hormone axis pulsatility studies.
• Tesamorelin — GHRH analogue, originally developed for HIV-associated lipodystrophy and used in visceral-fat metabolic research.
• Melanotan II — non-selective melanocortin receptor agonist, studied in pigmentation and appetite-signalling pathways.
• MOTS-c — mitochondrially-encoded peptide implicated in metabolic homeostasis and insulin sensitivity research.

Browse all of these in the catalogue.

Editorial note on NAD+

NAD+ is not a peptide — it is a dinucleotide cofactor — and it is listed separately within the full peptide catalogue only because researchers commonly source it from the same vendors. Its UK regulatory position differs: oral NAD+ precursors are generally treated as food supplements, whereas injectable NAD+ preparations risk classification as unlicensed medicinal products if marketed for human use [1]. Apply the same CoA and HPLC standards to NAD+ as to peptide stock, but recognise it falls under a separate regulatory framework.

A decision framework: five criteria for any supplier

Apply these five criteria to any peptide supplier before raising a purchase order.

1. Purity verification. Look for batch-specific HPLC certificates of analysis from UKAS-accredited ISO/IEC 17025 laboratories, showing ≥95% purity with chromatogram and mass-spectrometry data tied to the lot number on the vial [3][7].
2. Regulatory compliance. Each product page and CoA should carry an unambiguous "for research use only, not for human consumption" label, with no dosing instructions and no medicinal claims [1][6].
3. Format match. A supplier should stock both lyophilised powder vials and select pen formats. Lyophilised powder is the defensible research format; prefilled pens suit longitudinal protocols. See the full catalogue, including the semaglutide research peptide.
4. Pricing and currency transparency. GBP pricing inclusive of applicable taxes, end-to-end — no checkout-stage USD conversion, no dynamic FX surcharge.
5. Shipping reliability. Tracked, discreet UK dispatch with cold-chain packaging where required and named-courier tracking.

The science behind peptide research at JCSG

The Joint Center for Structural Genomics (JCSG) is a structural-biology consortium whose work on protein crystallography, NMR, and high-throughput structure determination underpins our editorial framework for evaluating peptide quality. That background matters because the same analytical discipline used to resolve protein structures — HPLC purification, mass spectrometry, NMR confirmation — is what you will find on every JCSG.org certificate of analysis.

Our internal contributors draw directly on this experience. Anna Sheydina (Postdoctoral Associate) and Caitlin Steckler (Research Assistant) have worked on structural characterisation pipelines, while Pedro Serrano (NMR Core Manager) oversees the spectroscopic verification methods that inform how we read vendor CoAs. Their published editorial on from protein structures to peptide therapeutics and on understanding protein-peptide interactions sets the scientific basis for the quality criteria applied across our full peptide catalogue, including the Semaglutide research peptide.

Research peptides for UK delivery

Download the batch-specific CoA for the Semaglutide research peptide or any other compound in the catalogue and verify it against the seven-point checklist above. Orders ship tracked and discreet to UK addresses with cold-chain packaging where required.

Browse the full research peptide catalogue.